GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Insider Ownership

ZBIO (Zenas BioPharma) Insider Ownership : 0.75 % (As of Apr. 12, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zenas BioPharma's insider ownership is 0.75%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zenas BioPharma's Institutional Ownership is 75.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zenas BioPharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Zenas BioPharma Insider Ownership Historical Data

The historical data trend for Zenas BioPharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Insider Ownership Chart

Zenas BioPharma Historical Data

The historical data trend for Zenas BioPharma can be seen below:

2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Insider Ownership 0.41 0.39 0.41 0.58 0.58 0.75 0.75

Zenas BioPharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Zenas BioPharma Business Description

Traded in Other Exchanges
N/A
Address
852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.